Business Description
Lisata Therapeutics Inc
NAICS : 325414
SIC : 8099
ISIN : US1280582032
Total Employee Number:
21Description
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 277.87 | |||||
Equity-to-Asset | 0.78 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -54.5 | |||||
Beneish M-Score | -6.61 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 42.8 | |||||
3-Year EPS without NRI Growth Rate | 42.8 | |||||
3-Year FCF Growth Rate | 23.7 | |||||
3-Year Book Growth Rate | -41.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 21.15 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 19.11 | |||||
9-Day RSI | 34.4 | |||||
14-Day RSI | 42.14 | |||||
3-1 Month Momentum % | -30.7 | |||||
6-1 Month Momentum % | 73.26 | |||||
12-1 Month Momentum % | 47.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.23 | |||||
Quick Ratio | 4.23 | |||||
Cash Ratio | 3.94 | |||||
Days Sales Outstanding | 1424.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.8 | |||||
Shareholder Yield % | -1.82 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -10178.24 | |||||
Net Margin % | -9618.24 | |||||
EBITDA Margin % | -10116.47 | |||||
FCF Margin % | -8026.71 | |||||
OCF Margin % | -8026.71 | |||||
ROE % | -91.31 | |||||
ROA % | -75.91 | |||||
ROIC % | -8110.82 | |||||
3-Year ROIIC % | -2920.02 | |||||
ROC (Joel Greenblatt) % | -48603.93 | |||||
ROCE % | -97.61 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 168.95 | |||||
PB Ratio | 2.68 | |||||
Price-to-Tangible-Book | 2.67 | |||||
EV-to-EBIT | -0.41 | |||||
EV-to-Forward-EBIT | -0.29 | |||||
EV-to-EBITDA | -0.41 | |||||
EV-to-Forward-EBITDA | -0.29 | |||||
EV-to-Revenue | 41.5 | |||||
EV-to-Forward-Revenue | 0.76 | |||||
EV-to-FCF | -0.52 | |||||
| Price-to-Net-Current-Asset-Value | 2.67 | |||||
| Price-to-Net-Cash | 2.96 | |||||
Earnings Yield (Greenblatt) % | -243.9 | |||||
FCF Yield % | -46.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lisata Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.146 | ||
| EPS (TTM) (€) | -1.599 | ||
| Beta | 1.3011 | ||
| 3-Year Sharpe Ratio | 0.24 | ||
| 3-Year Sortino Ratio | 0.67 | ||
| Volatility % | 167.43 | ||
| 14-Day RSI | 42.14 | ||
| 14-Day ATR (€) | 0.058695 | ||
| 20-Day SMA (€) | 2.921 | ||
| 12-1 Month Momentum % | 47.52 | ||
| 52-Week Range (€) | 1.5 - 4.34 | ||
| Shares Outstanding (Mil) | 9.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lisata Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lisata Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 120 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 119 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 29 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 28 days | ||
| First quarter earnings results for 2026 | 2026-05-11 | 2.68 (+0.00%) | ||
| Annual report for 2025 | 2026-03-12 | 4.26 (+0.00%) | ||
| Third quarter earnings conference call for 2025 | 2025-11-06 16:30 | 2.08 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 2.08 (+0.00%) | ||
| Guidance call for 2025 | 2025-10-20 10:30 | 2.06 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-07 16:30 | 2.44 (+0.00%) |
Show
Entries
Lisata Therapeutics Inc Frequently Asked Questions
What is Lisata Therapeutics Inc(FRA:8NE)'s stock price today?
The current price of FRA:8NE is €2.78. The 52 week high of FRA:8NE is €4.34 and 52 week low is €1.50.
When is next earnings date of Lisata Therapeutics Inc(FRA:8NE)?
The next earnings date of Lisata Therapeutics Inc(FRA:8NE) is 2026-08-07 Est..
Does Lisata Therapeutics Inc(FRA:8NE) pay dividends? If so, how much?
Lisata Therapeutics Inc(FRA:8NE) does not pay dividend.
Press Release
Articles on Lisata Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers